Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,226 |
Reported balance
After 2026-08-31 transaction · row 1
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 1,288 · Balance 33,226 F1: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Astria Therapeutics, Inc.
Report date January 23, 2026 · Filed January 23, 2026
Section 16 reporting ended · disclosed 2026-01-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 1
1 source rowRow 1 · 2026-01-23 · Disposition to issuer · Disposed 4,377 · Balance 0 F1: This number has been adjusted to reflect the 1-for-10 reverse stock split the Issuer effected on December 28, 2018 and the 1-for-6 reverse stock split the Issuer effected on August 19, 2021. F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of Issuer common stock, excluding shares held by the Issuer, BioCryst, or their wholly owned subsidiaries or dissenting stockholders, that was issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.51 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-23 · Disposition to issuer · Disposed 195,000 · Balance 0 F3: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.41 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-23 · Disposition to issuer · Disposed 761,000 · Balance 0 F3: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: This number has been adjusted to reflect the 1-for-10 reverse stock split the Issuer effected on December 28, 2018 and the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.
F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of Issuer common stock, excluding shares held by the Issuer, BioCryst, or their wholly owned subsidiaries or dissenting stockholders, that was issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to withholding taxes.
F3: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 20:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,288 | $9.70 | $12,493.60 |
DisclosureSEC source: 0000882796-26-000063 · form4.xml · nonDerivative · entry 1 Milne Jill C. · CIK 0001644246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,226 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:32 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 33,540 | $0.00 Strike: $8.50 | $0.00 |
DisclosureSEC source: 0000882796-26-000055 · form4.xml · derivative · entry 2 Milne Jill C. · CIK 0001644246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,540 Underlying: Common Stock · 33,540 shares Expires 2036-06-11 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:32 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 15,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000882796-26-000055 · form4.xml · nonDerivative · entry 1 Milne Jill C. · CIK 0001644246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,938 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:16 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,262 | $8.91 | $11,244.42 |
DisclosureSEC source: 0000882796-26-000033 · form4.xml · nonDerivative · entry 1 Milne Jill C. · CIK 0001644246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,644 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:36 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 528 | $8.75 | $4,620.00 |
DisclosureSEC source: 0000882796-26-000013 · form4.xml · nonDerivative · entry 1 Milne Jill C. · CIK 0001644246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,382 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 100% of the prorated quarterly cash Board Member retainer of $4,625. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 16:33 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Disposition to issuerStock Option (Right to Buy) · Derivative | 761,000 | Not disclosed Strike: $6.41 | Not disclosed |
DisclosureSEC source: 0000905148-26-000322 · form4.xml · derivative · entry 3 Milne Jill C. · CIK 0001644246 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 761,000 shares Expires not disclosed F3 · price: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F3 · derivative.exercise_date: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F3 · derivative.expiration_date: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 16:33 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Disposition to issuerStock Option (Right to Buy) · Derivative | 195,000 | Not disclosed Strike: $6.51 | Not disclosed |
DisclosureSEC source: 0000905148-26-000322 · form4.xml · derivative · entry 2 Milne Jill C. · CIK 0001644246 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 195,000 shares Expires not disclosed F3 · price: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F3 · derivative.exercise_date: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F3 · derivative.expiration_date: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 16:33 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Disposition to issuerCommon Stock | 4,377 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-26-000322 · form4.xml · nonDerivative · entry 1 Milne Jill C. · CIK 0001644246 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: This number has been adjusted to reflect the 1-for-10 reverse stock split the Issuer effected on December 28, 2018 and the 1-for-6 reverse stock split the Issuer effected on August 19, 2021. F2 · price: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of Issuer common stock, excluding shares held by the Issuer, BioCryst, or their wholly owned subsidiaries or dissenting stockholders, that was issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to withholding taxes. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 22:22 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 26,684 | $0.00 Strike: $6.79 | $0.00 |
DisclosureSEC source: 0000882796-26-000003 · form4.xml · derivative · entry 3 Milne Jill C. · CIK 0001644246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,684 Underlying: Common Stock · 26,684 shares Expires 2036-01-23 F3 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. F4 · derivative.exercise_date: The option grant vests 1/36 per month over a 3-year period measured from the date of grant. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 22:22 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,272 | $0.00 | $0.00 |
DisclosureSEC source: 0000882796-26-000003 · form4.xml · nonDerivative · entry 2 Milne Jill C. · CIK 0001644246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,854 F2 · shares: Automatic non-employee director grant of restricted stock units pursuant to the BioCryst Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest in three equal annual installments beginning on the twelve-month anniversary of the date of grant. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 22:22 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 2,582 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000882796-26-000003 · form4.xml · nonDerivative · entry 1 Milne Jill C. · CIK 0001644246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,582 F1 · price: Received in exchange for 4,377 shares of Astria Therapeutics, Inc. ("Astria") common stock in connection with a merger (the "Merger"), pursuant to which Astria became a wholly owned subsidiary of BioCryst Pharmaceuticals, Inc. ("BioCryst"). Pursuant to the Merger, each share of Astria common stock (subject to certain inapplicable exceptions) was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to applicable withholding taxes. On the last trading day before the effective date of the Merger, the closing price of Astria's common stock was $12.58 per share, and the closing price of BioCryst's common stock was $6.75 per share. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 16:07 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | GrantStock Option (Right to Buy) · Derivative | 761,000 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001104659-25-027776 · tm2510055-6_4seq1.xml · derivative · entry 1 Milne Jill C. · CIK 0001644246 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 761,000 Underlying: Common Stock · 761,000 shares Expires 2035-03-20 F1 · derivative.exercise_date: This option was granted on March 21, 2025 and is subject to vesting over a four-year period, with 25% of the 761,000 shares underlying the option upon grant vesting on the first anniversary of February 13, 2025 and the remainder vesting over the ensuing three years in equal monthly installments. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 16:06 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | GrantStock Option (Right to Buy) · Derivative | 534,600 | $0.00 Strike: $15.26 | $0.00 |
DisclosureSEC source: 0001104659-24-014617 · tm245876-5_4seq1.xml · derivative · entry 1 Milne Jill C. · CIK 0001644246 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 534,600 Underlying: Common Stock · 534,600 shares Expires 2034-02-07 F1 · derivative.exercise_date: This option was granted on February 8, 2024 and is subject to vesting over a four-year period, with 25% of the 534,600 shares underlying the option upon grant vesting on the first anniversary of February 8, 2024 and the remainder vesting over the ensuing three years in equal monthly installments. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 08:08 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $13.36 | $0.00 |
DisclosureSEC source: 0001104659-23-068347 · tm2317752-13_4seq1.xml · derivative · entry 1 Milne Jill C. · CIK 0001644246 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2033-01-31 F1 · date: This option was by granted effective as of February 1, 2023, subject to stockholder approval of an amendment to Astria Therapeutics, Inc.'s (the "Company") Amended and Restated 2015 Stock Incentive Plan to increase the number of shares available for issuance thereunder by 4,300,000 (the "Stock Plan Amendment Proposal"). The Company's stockholders approved the Stock Plan Amendment Proposal on June 2, 2023. F2 · derivative.exercise_date: This option was granted on February 1, 2023 and is subject to vesting over a four-year period, with 25% of the 275,000 shares underlying the option upon grant vesting on the first anniversary of February 1, 2023 and the remainder vesting over the ensuing three years in equal monthly installments. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 19:19 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | GrantStock Option (right to buy) · Derivative | 195,000 | $0.00 Strike: $6.51 | $0.00 |
DisclosureSEC source: 0001104659-22-030181 · tm228319-3_4seq1.xml · derivative · entry 1 Milne Jill C. · CIK 0001644246 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires not disclosed F1 · derivative.exercise_date: This option was granted on March 1, 2022, and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 17, 2022 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. F1 · derivative.expiration_date: This option was granted on March 1, 2022, and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 17, 2022 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 19:15 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 1,400,000 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001104659-21-075903 · tm2118270-4_4seq1.xml · derivative · entry 1 Milne Jill C. · CIK 0001644246 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400,000 Underlying: Common Stock · 1,400,000 shares Expires 2031-03-31 F1 · derivative.exercise_price: Represents the closing price of the common stock of Catabasis Pharmaceuticals, Inc. (the "Company") on April 1, 2021. F2 · derivative.exercise_date: This option was granted on April 1, 2021 subject to the approval by the stockholders of the Company of an increase in the number of shares of common stock available under the Company's Amended and Restated 2015 Stock Incentive Plan ("Proposal No. 4") at the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting"). Proposal No. 4 received the requisite approval at the Annual Meeting on June 2, 2021. The option is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of April 1, 2021 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 12:55 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $5.32 | $0.00 |
DisclosureSEC source: 0001179110-20-001597 · edgar.xml · derivative · entry 1 Milne Jill C. · CIK 0001644246 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-02-11 F1 · derivative.exercise_date: This option was granted on February 12, 2020, and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 12, 2020 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 08:40 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001179110-19-001940 · edgar.xml · derivative · entry 1 Milne Jill C. · CIK 0001644246 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-02-12 F1 · derivative.exercise_date: This option was granted on February 13, 2019 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 13, 2019 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
| September 07, 2018 Filed Sep 11, 2018 16:12 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001179110-18-011280 · edgar.xml · derivative · entry 1 Milne Jill C. · CIK 0001644246 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2028-09-06 F1 · derivative.exercise_date: This option was granted on September 7, 2018 and is subject to vesting over a two year period, with 50% of the shares vesting on the first anniversary of September 7, 2018 and the remainder vesting over the ensuing year at a rate of 4.1667% per month. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 16:01 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001179110-18-001881 · edgar.xml · derivative · entry 1 Milne Jill C. · CIK 0001644246 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2028-02-07 F1 · derivative.exercise_date: This option was granted on February 8, 2018 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 8, 2018 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
| February 09, 2017 Filed Feb 10, 2017 16:04 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001179110-17-002157 · edgar.xml · derivative · entry 1 Milne Jill C. · CIK 0001644246 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-02-08 F1 · derivative.exercise_date: This option was granted on February 9, 2017 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 9, 2017 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
| September 08, 2016 Filed Sep 12, 2016 16:14 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001179110-16-029553 · edgar.xml · derivative · entry 1 Milne Jill C. · CIK 0001644246 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2026-09-07 F1 · derivative.exercise_date: This option was granted on September 8, 2016 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of September 8, 2016 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
| September 08, 2016 Filed Sep 13, 2016 17:24 UTC Amendment | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001179110-16-029616 · edgar.xml · derivative · entry 1 Milne Jill C. · CIK 0001644246 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2026-09-07 F1 · derivative.exercise_price: This Form 4/A is being filed to correct the stated Conversion or Exercise Price of Derivative Security. The correct Exercise Price of the Derivative Security is $4.31 and was previously stated as $4.30. F2 · derivative.exercise_date: The option was granted on September 8, 2016 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of September 8, 2016 and the reminder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.